Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Recruiting

Phase 1

Phase 2

RiMO-301 & RadiotherapyStudy of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Sponsor:

Coordination Pharmaceuticals, Inc.

Code:

NCT05838729

Conditions

Head Neck Cancer

Intratumoral Injection

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RiMO-301

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-12. This information was provided to ClinicalTrials.gov by Coordination Pharmaceuticals, Inc. on 2025-02-12.